Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by StockNews.com

StockNews.com began coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a research report issued on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Roth Capital lowered Cyclacel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd.

Cyclacel Pharmaceuticals Price Performance

Shares of NASDAQ:CYCC opened at $0.32 on Wednesday. Cyclacel Pharmaceuticals has a 1 year low of $0.31 and a 1 year high of $4.00. The firm has a market capitalization of $2.00 million, a PE ratio of -0.03 and a beta of 0.38. The business’s 50 day moving average price is $0.52 and its 200-day moving average price is $1.06.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.36. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.01 million. Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%. As a group, analysts expect that Cyclacel Pharmaceuticals will post -1.95 earnings per share for the current year.

Institutional Trading of Cyclacel Pharmaceuticals

A hedge fund recently bought a new stake in Cyclacel Pharmaceuticals stock. Armistice Capital LLC purchased a new stake in shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 134,000 shares of the biotechnology company’s stock, valued at approximately $217,000. Armistice Capital LLC owned about 9.18% of Cyclacel Pharmaceuticals at the end of the most recent reporting period. 23.58% of the stock is currently owned by hedge funds and other institutional investors.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.